Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].

Klinicheskaia laboratornaia diagnostika - 1 Jul 2012

Abdullaeva A O, Glinshchikova O A, Suslova S A, Shadieva N Kh, Kolosova L Iu, Meshcheriakova L M, Vakhrusheva M V, Sudarikov A B

Abstract excerpt

The mutation V617F of gene JAK2 is detected in 95% of patients with genuine polycythemia, in 50% of patients with essential thrombocytemia and idiopathic myelofibrosis. The mutation V617F can be applied as a molecular marker of response to treatment in patients with chronic myeloproliferative dis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Chronic Disease
Share to Evaluation Studies as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polycythemia

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 22988798

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22988798-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].PMID 22988798Read ↗

[The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].Semantic proximity Read ↗

[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].Semantic proximity Read ↗

[A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].Semantic proximity Read ↗

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].Semantic proximity Read ↗

[The quantitative testing of V617F mutation in gen JAK2 using pyrosequencing technique].Semantic proximity Read ↗

Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

[Detection of JAK2V617F mutation rate by real-time fluorescent quantitative PCR using allele specific primer and TaqMan-MGB probe for dual inhibiting amplification of wild type alleles].Semantic proximity Read ↗

Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders.Semantic proximity Read ↗

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosisSemantic proximity Read ↗

A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresisSemantic proximity Read ↗

[Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia].Semantic proximity Read ↗

Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.